Key takeaways
- SS-31 is elamipretide, also called Bendavia in some studies: a four-amino-acid peptide that binds cardiolipin, a fat in the inner membrane of mitochondria.
- In the US it is the active ingredient of Forzinity, granted accelerated approval on 19 September 2025 for muscle strength in Barth syndrome; products sold online as “SS-31” are not that medicine.
- In the only completed placebo-controlled Barth syndrome trial (12 patients), it did not beat placebo on the primary endpoints; the approval rests on knee strength measured in the open-label extension, and a confirmatory trial is required.
- A phase 3 trial in 218 adults with mitochondrial myopathy and a phase 2 trial in 71 adults with heart failure did not meet their main goals.
- The label lists injection-site reactions in all 12 treated patients and serious allergic reactions; carcinogenicity studies have not been done.
01SS-31 at a glance
The short version, dated 18 November 2026.
| Question | SS-31 (elamipretide) |
|---|---|
| What it is | A peptide of four amino acids, D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2, that binds cardiolipin, a fat in the inner membrane of mitochondria. |
| Other names | Elamipretide, the name on the FDA label. Bendavia in some earlier studies. Forzinity is the brand of the approved US medicine. |
| Evidence tier | T1: randomised trials in people, including the four below; the three below in patient groups missed their primary endpoints. T3 (mouse) for the ageing research. |
| Human studies | Randomised trials include Barth syndrome (n=12), primary mitochondrial myopathy (n=218), heart failure (n=71) and healthy older adults (n=39). |
| United States | FDA-approved as Forzinity on 19 Sep 2025, under accelerated approval, for muscle strength in Barth syndrome only. In August 2026, FDA warning letters listed “SS-31” sold online by three sellers among unapproved new drugs. |
| European Union | No EU-wide authorisation (EMA data, 17 Nov 2026). Orphan designation for Barth syndrome since 20 May 2021, which is not an authorisation. |
| United Kingdom | No result for elamipretide or Forzinity on the emc medicines database (18 Nov 2026). |
| Australia | Not named in the Poisons Standard October 2026, and we found no group entry that would cover it (text searched 18 Nov 2026). |
| WADA | Not named on the 2026 or 2027 Prohibited List. |
02What is the SS-31 peptide?
SS-31 is the research name for elamipretide, a peptide of four amino acids: D-arginine, 2,6-dimethyltyrosine, lysine and phenylalanine amide. A 2021 paper describes elamipretide as “also referred to as SS-31 and Bendavia in the literature”.
FDA’s label calls it a “mitochondrial cardiolipin binder”. Mitochondria are the compartments that produce most of a cell’s energy. Cardiolipin is a fat in their inner membrane. In Barth syndrome, a rare inherited disorder, the EMA describes cardiolipin as deficient, and elamipretide was developed to bind it there.
The same name now covers a regulated medicine and products sold online; this page keeps them apart. How we grade the evidence below: evidence grades.
03Is SS-31 FDA-approved?
Not as sold online. Elamipretide is approved in the US only as Forzinity, for one use. On 19 September 2025, FDA granted accelerated approval to Forzinity (elamipretide), NDA 215244, “to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”.
Accelerated approval rests on an intermediate clinical endpoint, here knee extensor muscle strength. The label says continued approval “may be contingent upon verification and description of clinical benefit in a confirmatory trial”. FDA requires a randomised, placebo-controlled trial in patients aged 5 and older, and says it may withdraw the approval if that trial fails to verify benefit. The developer’s timetable puts the trial’s completion in September 2029.
The approval came on the second attempt. In May 2025, FDA declined the application, writing that the effectiveness of elamipretide “has not been established” for traditional approval, and pointed to knee strength as a possible route to accelerated approval.
Products sold online as “SS-31” are not that medicine. FDA warning letters dated 24 August 2026 to three online sellers listed their “SS-31”, labelled for research use, among unapproved new drugs.
The same pattern applies to bremelanotide: see PT-141. US drug law and peptides: are peptides legal in the US?
04What have human and animal studies of elamipretide measured?
Four of elamipretide’s randomised trials in people, and one mouse study. None tested a product sold online.
Barth syndrome, 2025 label (T1, n=12). In the crossover trial on the label, 12 males aged 12 to 35 each received elamipretide and placebo for 12 weeks, in a random sequence. Elamipretide “was not superior to placebo” on the two primary endpoints, distance walked in six minutes and a fatigue score. Ten continued in an open-label extension, where everyone knew they were receiving it. Knee strength increases “were not observed during the randomized trial but were observed during the extension period”. For the extension’s walking, fatigue and other measures of how patients function, FDA’s May 2025 letter raised concern about bias in effort-dependent measures when participants know they are receiving the drug; the same letter named knee strength as a possible basis for accelerated approval.
Primary mitochondrial myopathy, 2023 (T1, n=218). The phase 3 MMPOWER-3 trial randomised 218 adults with genetically confirmed mitochondrial myopathy to elamipretide or placebo for 24 weeks. It did not meet its primary endpoints, distance walked in six minutes and total fatigue.
Heart failure, 2020 (T1, n=71). The phase 2 PROGRESS-HF trial randomised 71 adults with heart failure with reduced ejection fraction to elamipretide or placebo for 4 weeks. Its main measure, the volume left in the heart’s main pumping chamber after each beat, did not change differently from placebo.
Older adults, 2021 (T1, small, n=39). A randomised, placebo-controlled study gave a single treatment to 39 healthy adults aged 60 to 85, chosen for poorly functioning mitochondria, and measured peak energy (ATP) production in a hand muscle. Right after treatment, the change versus placebo was borderline: p=0.055 for the absolute change and p=0.045 for the percentage change. By day 7 there was no difference, and fatigue resistance did not change. The developer, Stealth BioTherapeutics, funded the study.
Aged mice, 2013 (T3). Researchers measured energy production in the muscle of 27-month-old mice and reported that, one hour after a single treatment, it rose to the level of 5-month-old mice, with no visible effect in the young mice. They also reported more endurance after eight days. The abstract does not give the number of animals. These are mouse results.
05What does the approved label say about safety?
These figures come from the approved medicine’s trials and label. They do not describe products sold online.
- Injection-site reactions. In the Barth crossover trial, all 12 patients had a local reaction while on elamipretide, against 8 of 12 on placebo. Redness occurred in 12, against 3 on placebo.
- Allergic reactions. The label says hypersensitivity reactions, “including serious allergic reactions requiring emergency medical intervention”, have been reported, among them rash, other skin reactions and cough, and that they may occur “within minutes to months” after starting. The label lists serious allergy to elamipretide as a contraindication.
- Eosinophils. Counts of eosinophils, a type of white blood cell, rose frequently with 30 days or more of exposure, peaked around day 90 and were not linked to symptoms.
- Cancer risk. “Carcinogenicity studies have not been conducted with elamipretide,” the label says. In May 2025, FDA wrote that its human carcinogenic potential “is uncertain”. It now requires a 26-week mouse study and a 2-year rat study; the rat study is due to finish in October 2029.
How to read safety information like this: side effects, documented vs unknown.
06Is SS-31 approved in the UK, the EU or Australia?
European Union. No EU-wide authorisation: the EMA’s data on centrally authorised medicines (17 November 2026) lists no elamipretide medicine. The EMA lists two orphan designations for elamipretide: Barth syndrome (20 May 2021) and myopathic mitochondrial DNA depletion syndrome (16 May 2022). In the EMA’s words, “Orphan designation does not mean the medicine is available or authorised for use.”
United Kingdom. A search of the emc medicines database for elamipretide and for Forzinity returned no results on 18 November 2026. UK medicines law and peptides: are peptides legal in the UK?
Australia. Elamipretide is not named in the Poisons Standard October 2026, and we found no group entry in it that would cover it. Other Australian rules on unapproved peptide products: are peptides legal in Australia?
Sport. Elamipretide is not named on WADA’s Prohibited List for 2026 or 2027. Athletes in tested sport should check the status of any substance with their national anti-doping organisation. See peptides and anti-doping.
07What don’t we know about SS-31?
- Whether elamipretide gives people with Barth syndrome a clinical benefit. That is what the confirmatory trial must show, and it is not due to finish before September 2029.
- Any effect on ageing in people. The one study in older adults measured a muscle energy marker after a single treatment, not health outcomes, and the clearest ageing results are in mice. More: longevity research.
- Long-term cancer risk. The required carcinogenicity studies are not finished.
- What a vial sold online as “SS-31” contains. Only a lab report on that vial’s own lot can show it, and only for what the lab tested: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.